New prostate cancer screening method aims to cut unnecessary biopsies
NCT ID NCT06238661
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study is testing a new screening pathway for prostate cancer in men aged 55-65. Instead of relying only on PSA blood tests, participants with elevated PSA will also get a risk assessment and an MRI. The goal is to better distinguish between slow-growing cancers that don't need treatment and aggressive ones that do, potentially reducing unnecessary biopsies and improving early detection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this screening approach could reduce unnecessary biopsies and better identify aggressive prostate cancers early.
- What could go wrong
- This is a pilot study, so results are preliminary. The new method may not prove better than current PSA-only screening in larger populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fondazione del Piemonte per l'Oncologia
Candiolo, Italy, 10060, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?